Efficacy and safety of the Ad-GM•CAIX dendritic cell-based vaccine in treating in vivo metastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy

被引：0
|
作者：
Rampersaud, Edward N. [1 ]
Said, Jonathan W. [2 ]
Bot, Adrian [3 ]
Birkhaueser, Frederic D. [1 ]
Kroeger, Nils [1 ]
Zeng, Gang [1 ]
Kabbinavar, Fairooz F. [1 ]
Ribas, Antoni [4 ]
Pantuck, Allan J. [1 ]
Belldegrun, Arie S. [1 ]
Riss, Joseph [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
[3] Kite Pharma Inc, Los Angeles, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2819
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2819
引用
收藏
页数：2
相关论文
共 37 条
  • [21] Pharmacoeconomic analysis of sorafenib and sunitinib for first line treatment of metastatic renal cell carcinoma (MRCC) compared with combination therapy of Bevacizumab, Gemcitabine, and Capecitabine (BGC) at a large cancer center
    Smith, W. D.
    Arbuckle, R.
    VALUE IN HEALTH, 2007, 10 (03) : A124 - A124
  • [22] Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial
    Powles, Thomas
    Atkins, Michael B.
    Escudier, Bernard
    Motzer, Robert J.
    Rini, Brian, I
    Fong, Lawrence
    Joseph, Richard W.
    Pal, Sumanta K.
    Sznol, Mario
    Hainsworth, John
    Stadler, Walter M.
    Hutson, Thomas E.
    Ravaud, Alain
    Bracarda, Sergio
    Suarez, Cristina
    Choueiri, Toni K.
    Reeves, James
    Cohn, Allen
    Ding, Beiying
    Leng, Ning
    Hashimoto, Kenji
    Huseni, Mahrukh
    Schiff, Christina
    McDermott, David F.
    EUROPEAN UROLOGY, 2021, 79 (05) : 665 - 673
  • [23] IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
    Rini, Brian I.
    Stenzl, Arnulf
    Zdrojowy, Romuald
    Kogan, Mikhail
    Shkolnik, Mikhail
    Oudard, Stephane
    Weikert, Steffen
    Bracarda, Sergio
    Crabb, Simon J.
    Bedke, Jens
    Ludwig, Joerg
    Maurer, Dominik
    Mendrzyk, Regina
    Wagner, Claudia
    Mahr, Andrea
    Fritsche, Jens
    Weinschenk, Toni
    Walter, Steffen
    Kirner, Alexandra
    Singh-Jasuja, Harpreet
    Reinhardt, Carsten
    Eisen, Tim
    LANCET ONCOLOGY, 2016, 17 (11): : 1599 - 1611
  • [24] A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina
    Baig, Mahadi A.
    Dutta, Lea
    Li, Di
    Young, Louise
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 169 - 169
  • [26] First-line therapy in advanced Renal Cell Carcinoma A randomized, open-label Phase-III-Study Evaluating the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib compared to Sunitinib Monotherapy as First-Line Treatment for locally advanced or metastatic Renal Cell Carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO
    Rexer, H.
    Bedke, J.
    UROLOGE, 2017, 56 (03): : 385 - 386
  • [27] ASSESSMENT OF EFFICACY, SAFETY AND QUALITY OF LIFE OF 110 PATIENTS TREATED WITH SUNITINIB AS FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA: EXPERIENCE IN REAL WORLD CLINICAL PRACTICE IN JAPAN
    Harada, Ken-ichi
    Miyake, Hideaki
    Fujisawa, Masato
    JOURNAL OF UROLOGY, 2015, 193 (04): : E870 - E870
  • [28] Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    Motzer, R. J.
    Hutson, T. E.
    Olsen, M. R.
    Hudes, G. R.
    Burke, J. M.
    Edenfield, W. J.
    Wilding, G.
    Martell, B.
    Hariharan, S.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Fowles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan
    Miyake, Hideaki
    Miyazaki, Akira
    Harada, Ken-ichi
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2014, 31 (06)
1234